Pharmafile Logo

LGBTQ+

- PMLiVE

Personalised medicine: driving a need for greater diversity in clinical trials

Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today.

Innovative Trials

Lucid Group Welcomes a New Cohort of Graduates into its Futures Academy

We are excited to welcome this year’s cohort of graduates into our Lucid Futures Academy, which is now into its sixth year after being launched in Oct 2017.The Futures Academy...

Lucid Group Communications Limited

- PMLiVE

Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19

The FDA also issued an EUA for the treatment to include non-hospitalised paediatric patients 12 years and under who are at high risk of disease progression

- PMLiVE

SMC approves Parkinson’s disease treatment Ongentys

The once-daily additional oral treatment for patients living with Parkinson’s disease is now accepted for use within NHS Scotland

- PMLiVE

Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events

With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay

- PMLiVE

PM announces plans to lift England’s COVID-19 restrictions

Following the announcement, England is set to remove its ‘Plan B’ COVID-19 restrictions over the next week

- PMLiVE

Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment

The study evaluated the combination of Lenvima plus Keytruda versus chemotherapy for patients diagnosed with advanced, metastatic, or recurrent endometrial carcinoma

Developing Innovative Digital Strategies to Engage Patients

Caitlin Wagner, Associate Marketing Director at Pharming, shares her expertise on innovative patient engagement strategies, including the roles of mobile apps and social media, the impact of the COVID-19 pandemic...

Impetus Digital

- PMLiVE

GSK appoint Tony Wood as chief scientific officer

Wood’s appointment will follow the exit of Dr Hal Barron, effective from August 2022

- PMLiVE

Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results

The trial confirms the potential benefit of targeting inflammation in prurigo nodularis

- PMLiVE

Cervical Cancer Prevention Month

In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer

Innovative Trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links